Sažetak sa skupa

https://doi.org/10.26800/LV-145-supl2-CR31

Diabetes Mellitus and diabetic ketoacidosis associated with pembrolizumab

Karla Lauš ; Faculty of Medicine, Josip Juraj Strossmayer University of Osijek, Osijek
Hrvoje Centner
Ema Schönberger
Silvija Canecki-Varžić

Sažetak

Diabetic ketoacidosis (DKA) is an acute, life-threatening complication of diabetes mellitus (DM) and is characterized by hyperglycemia, hyperketonemia and metabolic acidosis. With the increasing use of immune checkpoint inhibitors (ICIs), such as pembrolizumab in cancer therapy, it’s important tounderstand immune-related adverse events that comes with it.

Ključne riječi

diabetes mellitus; diabetic ketoacidosis; pembrolizumab

Hrčak ID:

303546

URI

https://hrcak.srce.hr/303546

Datum izdavanja:

23.4.2023.

Posjeta: 446 *